Biomedical Bonding Expands Its Clinical Network with Prof. Paul Ackermann

Biomedical Bonding AB has entered into a Key Opinion Leader collaboration with Prof. Paul Ackermann, Professor of Orthopaedic Surgery at Karolinska Institutet and Consultant Orthopaedic Surgeon at Karolinska University Hospital, further expanding the clinical network surrounding the Bonevolent® platform.

With more than 25 years of clinical and academic experience, Prof. Ackermann's work spans orthopaedic trauma, fracture care, musculoskeletal injury, tissue repair, and translational research. His engagement adds valuable clinical expertise to Biomedical Bonding's growing network of surgeons and researchers helping inform the future development of the Bonevolent® platform.

As part of his approved independent clinical perspective, Prof. Ackermann comments:

Bonevolent is a clinically interesting concept because it addresses one of the core challenges in fracture surgery: achieving stable fixation on complex and irregular bone surfaces. If validated, adhesive-based fixation could become an important complement to existing plates and screws in selected orthopaedic indications.

Prof. Ackermann further highlights that achieving stable fixation in complex fractures often requires balancing biomechanics, bone biology, soft-tissue conditions, and challenging anatomy. Conventional plates, screws, and wires remain powerful treatment options, but limitations can arise when bone fragments are small, fragile, osteoporotic, or anatomically difficult to capture. Concepts capable of conforming more closely to irregular bone geometry are therefore clinically interesting when supported by robust biomechanical, biological, and clinical validation.

As Biomedical Bonding continues to expand its clinical engagement activities, collaborations with experienced surgeons play an important role in identifying unmet clinical needs, evaluating new treatment concepts, and ensuring that innovation remains closely connected to the realities of surgical practice.

Michael Malkoch, CEO and Founder of Biomedical Bonding, comments:

The development of new fracture fixation technologies requires more than scientific and engineering expertise. It requires continuous dialogue with surgeons who understand the challenges faced in the operating room every day. Paul's experience in orthopaedic trauma, tissue repair, and translational research brings an important clinical perspective as we continue to advance the Bonevolent® platform.

The collaboration reflects Biomedical Bonding's commitment to building long-term partnerships between researchers, engineers, and clinicians as the company continues to develop next-generation solutions for fracture fixation and bone repair.

Prof. Ackermann's affiliation with Karolinska Institutet and Karolinska University Hospital is provided for identification purposes only and does not imply endorsement by either institution.